Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker

BACKGROUND: Tumor mutational burden (TMB) is a significant predictor of immune checkpoint inhibitors (ICIs) efficacy. This study investigated the correlation between deep learning radiomic biomarker and TMB, including its predictive value for ICIs treatment response in patients with advanced non-sma...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Bingxi, Dong, Di, She, Yunlang, Zhou, Caicun, Fang, Mengjie, Zhu, Yongbei, Zhang, Henghui, Huang, Zhipei, Jiang, Tao, Tian, Jie, Chen, Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342823/
https://www.ncbi.nlm.nih.gov/pubmed/32636239
http://dx.doi.org/10.1136/jitc-2020-000550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342823/
https://www.ncbi.nlm.nih.gov/pubmed/32636239
http://dx.doi.org/10.1136/jitc-2020-000550

Ejemplares similares